CanFite Reported Namodenoson In Predominantly Third-Line Pancreatic Cancer Patients Demonstrated Durable Survival Despite Advanced Disease;
CanFite Reported Namodenoson In Predominantly Third-Line Pancreatic Cancer Patients Demonstrated Durable Survival Despite Advanced Disease; Second-Line Patient Remains Alive More Than 18 Months
Story updates
11:16:19 AM UTC
SQUAWKNEWS
NKE: -9% | Nike shares are trading lower. The company reported Q4 financial results. BE: 12% | Bloom Energy shares are trading higher after the company announced it expanded its AI infrastructure partnership with Brookfield. CANF: 100% | CanFite Reported Namodenoson In Predominantly Third-Line Pancreatic Cancer Patients Demonstrated Durable Survival Despite Advanced Disease; Second-Line Patient Remains Alive More Than 18 Months
NKE: -9% | Nike shares are trading lower.
The company reported Q4 financial results.
BE: 12% | Bloom Energy shares are trading higher after the company announced it expanded its AI infrastructure partnership with Brookfield.
CANF: 100% | CanFite Reported Namodenoson In Predominantly Third-Line Pancreatic Cancer Patients Demonstrated Durable Survival Despite Advanced Disease; Second-Line Patient Remains Alive More Than 18 Months